New device aims to limit heart damage during heart attacks

NCT ID NCT04969471

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device called enVast that removes blood clots from heart arteries during a severe heart attack (STEMI). About 148 adults with large clots will either get standard care or standard care plus the enVast device. The goal is to see if the device reduces the size of heart muscle damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

enVast coronary thrombectomy system (a device to remove blood clots from heart arteries)

What this could lead to

If successful, this device could reduce heart muscle damage during a heart attack, potentially improving recovery and long-term heart function.

What could go wrong

This is a mid-stage trial with 148 participants, so results may not apply to all patients. The device may not work better than standard treatment and carries risks like vessel injury or bleeding.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istituto Cardiocentro Ticino

    Lugano, Switzerland